Search by drug, manufacturer, or indication

Displaying 721 - 730 of 1165

Tegsedi (inotersen)

Status:

Concluded with an LOI

Manufacturer:

Akcea Therapeutics Inc.

Indication:

Hereditary transthyretin-mediated amyloidosis

Last updated April 30, 2020

Lorbrena (lorlatinib)

Status:

Negotiations were not pursued

Manufacturer:

Pfizer Canada ULC

Indication:

Non-Small Cell Lung Cancer (ALK+)

Last updated April 21, 2020

Mezera (mesalazine)

Status:

Concluded with an LOI

Manufacturer:

AVIR Pharma Inc.

Indication:

Ulcerative Colitis

Last updated April 21, 2020

Kanjinti (trastuzumab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer

Last updated April 16, 2020

Lokelma (sodium zirconium cyclosilicate)

Status:

Negotiations were not pursued

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Hyperkalemia

Last updated April 16, 2020

Humira (citrate-free) (adalimumab citrate-free)

Status:

Concluded without agreement

Manufacturer:

AbbVie Corporation

Indication:

Multiple Indications

Last updated April 16, 2020

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Squamous Non-Small Cell Lung Cancer

Last updated April 15, 2020

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Melanoma adjuvant therapy

Last updated April 15, 2020

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated April 15, 2020

Radicava (edaravone)

Status:

Concluded with an LOI

Manufacturer:

Mitsubishi Tanabe Pharma Canada, Inc.

Indication:

Amyotrophic Lateral Sclerosis (ALS)

Last updated April 15, 2020